Limited immunogenicity of HIV CD8+ T-cell epitopes in acute clade C virus infection

Journal of Infectious Diseases

Volumn 204, Issue 5, 2011, Pages 768-776

  Radebe, Mopo ^a   Nair, Kriebashnie ^a   Chonco, Fundisiwe ^a   Bishop, Karen ^a   Wright, Jaclyn K ^a   Van Stok, Mary Der ^a   Bassett, Ingrid V ^b   Mncube, Zenele ^a   Altfeld, Marcus ^a,b   Walker, Bruce D ^a,b,c   Ndung'u, Thumbi ^a,b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b HARVARD UNIVERSITY   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTIN; EPITOPE; GAG PROTEIN; INTERFERON ANTIBODY; PHYTOHEMAGGLUTININ; T LYMPHOCYTE ANTIGEN; VIRUS RNA;

AMINO ACID SEQUENCE; ANTIGEN EXPRESSION; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL VIABILITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE SEVERITY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 CLADE C INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN TARGETING; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD;

ACUTE DISEASE; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSPOT ASSAY; EPITOPES, T-LYMPHOCYTE; GENE PRODUCTS, GAG; GENE PRODUCTS, NEF; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; INTERFERON-GAMMA; RNA, VIRAL; TIME FACTORS; VIRAL LOAD;

EID: 80051761583     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir394     Document Type: Article

References (50)

1. UNAIDS. Report on the global AIDS epidemic. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS (UNAIDS), 2009.
2. National Department of Health. National antenatal sentinel HIV and syphilis prevalence survey: Republic of South Africa. Pretoria: National Department of Health of South Africa, 2009.
3. UNAIDS. Report on the global AIDS epidemic. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS (UNAIDS), 2008.
4. Virgin HW, Walker BD. Immunology and the elusive AIDS vaccine. Nature 2010; 464:224-231
5. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-665
6. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, doubleblind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194:1661-1671 (Pubitemid 44901996)
7. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a doubleblind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-1893
8. McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008; 372:1894-1905
9. Hansen SG, Vieville C, Whizin N, et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009; 15:293-299
10. Liu J, O'Brien KL, Lynch DM, et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009; 457:87-91.
11. Wilson NA, Keele BF, Reed JS, et al. Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J Virol 2009; 83:6508-6521
12. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68:6103-6110
13. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68: 4650-4655 (Pubitemid 24183063)
14. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 2009; 206:1253-1272
15. Borrow P, Lewicki H, Wei X, et al. Antiviral pressure exerted by HIV-1- specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997; 3:205-211 (Pubitemid 27064706)
16. Allen TM, O'Connor DH, Jing P, et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 2000; 407:386-390
17. Cao J,McNevin J, Holte S, Fink L, Corey L,McElrathMJ. Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. J Virol 2003; 77:6867-6878 (Pubitemid 36666880)
18. Allen TM, Altfeld M, Geer SC, et al. Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol 2005; 79:13239-13249 (Pubitemid 41508139)
19. Matano T, Kobayashi M, Igarashi H, et al. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med 2004; 199:1709-1718 (Pubitemid 38822004)
20. Jin X, Bauer DE, Tuttleton SE, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virusinfected macaques. J Exp Med 1999; 189:991-998 (Pubitemid 29149355)
21. Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999; 283:857-860
22. Yu XG, Addo MM, Rosenberg ES, et al. Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection. J Virol 2002; 76:8690-8701 (Pubitemid 34864064)
23. Lichterfeld M, Yu XG, Le Gall S, Altfeld M. Immunodominance of HIV-1-specific CD8(+) T-cell responses in acute HIV-1 infection: at the crossroads of viral and host genetics. Trends Immunol 2005; 26:166-171 (Pubitemid 40312524)
24. Altfeld M, Kalife ET, Qi Y, et al. HLA alleles associated with delayed progression to AIDS contribute strongly to the initial CD8(+) T cell response against HIV-1. PLoS Med 2006; 3:e403.
25. Streeck H, Jolin JS, Qi Y, et al. Human immunodeficiency virus type 1- specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J Virol 2009; 83:7641-7648
26. Turnbull EL, Wong M, Wang S, et al. Kinetics of expansion of epitopespecific T cell responses during primary HIV-1 infection. J Immunol 2009; 182:7131-7145
27. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871-1879 (Pubitemid 37070272)
28. Bassett IV, Chetty S, Giddy J, et al. Screening for acute HIV infection in South Africa: finding acute and chronic disease. HIV Med 2011; 12:46-53.
29. van Loggerenberg F, Mlisana K, Williamson C, et al. Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS One 2008; 3:e1954.
30. Kiepiela P, Ngumbela K, Thobakgale C, et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007; 13:46-53. (Pubitemid 46067385)
31. Thobakgale CF, Ramduth D, Reddy S, et al. Human immunodeficiency virus-specific CD8+ T-cell activity is detectable from birth in the majority of in utero-infected infants. J Virol 2007; 81:12775-12784 (Pubitemid 350156915)
32. Addo MM, Yu XG, Rathod A, et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 2003; 77:2081-2092 (Pubitemid 36110021)
33. Zhao J, Lou Y, Pinczewski J, et al. Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr- SIVenv/rev and Ad5hr-SIVgag recombinants. Vaccine 2003; 21:4022-4035 (Pubitemid 37338230)
34. Wright JK, Brumme ZL, Carlson JM, et al. Gag-protease-mediated replication capacity in HIV-1 subtype C chronic infection: associations with HLA type and clinical parameters. J Virol 2010; 84: 10820-10831
35. Huang X, Zhang J. Methods for comparing a DNA sequence with a protein sequence. Comput Appl Biosci 1996; 12:497-506. (Pubitemid 27067442)
36. Altfeld M, Rosenberg ES, Shankarappa R, et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 2001; 193:169-180 (Pubitemid 32524449)
37. Alter G, Merchant A, Tsoukas CM, et al. Human immunodeficiency virus (HIV)-specific effector CD8 T cell activity in patients with primary HIV infection. J Infect Dis 2002; 185:755-765 (Pubitemid 34226203)
38. Gray CM, Mlotshwa M, Riou C, et al. Human immunodeficiency virus-specific gamma interferon enzyme-linked immunospot assay responses targeting specific regions of the proteome during primary subtype C infection are poor predictors of the course of viremia and set point. J Virol 2009; 83:470-478
39. Brander C, Goulder P. The evolving field of HIV CRL epitope mapping: new approaches for the identification of novel epitopes. In: Korber BTM, Brander C, Walker BD, et al, eds. HIV molecular database. Los Alamos, NM: Los Alamos National Laboratory, 2000.
40. Altfeld M, Addo MM, Shankarappa R, et al. Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J Virol 2003; 77:7330-7340 (Pubitemid 36734501)
41. Sun Y, Iglesias E, Samri A, et al. A systematic comparison of methods to measure HIV-1 specific CD8 T cells. J Immunol Methods 2003; 272:23-34. (Pubitemid 36050742)
42. Lichterfeld M, Yu XG, Cohen D, et al. HIV-1 Nef is preferentially recognized by CD8 T cells in primary HIV-1 infection despite a relatively high degree of genetic diversity. AIDS 2004; 18:1383-1392 (Pubitemid 38925130)
43. Masemola A, Mashishi T, Khoury G, et al. Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load. J Virol 2004; 78:3233-3243 (Pubitemid 38568263)
44. Novitsky V, Gilbert P, Peter T, et al. Association between virus-specific T-cell responses and plasma viral load in human immunodeficiency virus type 1 subtype C infection. J Virol 2003; 77:882-890 (Pubitemid 36055510)
45. Masemola AM, Mashishi TN, Khoury G, et al. Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype C HIV type 1 infection from southern Africa. J Immunol 2004; 173:4607-4617 (Pubitemid 39280694)
46. Betts MR, Ambrozak DR, Douek DC, et al. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol 2001; 75:11983-11991 (Pubitemid 33115870)
47. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIVspecific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443:350-354 (Pubitemid 44435155)
48. Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006; 12:1198-1202 (Pubitemid 44527357)
49. Petrovas C, Casazza JP, Brenchley JM, et al. PD-1 is a regulator of virusspecific CD8+ T cell survival in HIV infection. J Exp Med 2006; 203:2281-2292 (Pubitemid 44498363)
50. Kaufmann DE, Kavanagh DG, Pereyra F, et al. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol 2007; 8:1246-1254 (Pubitemid 350011764)